<?xml version="1.0" encoding="UTF-8"?>
<results title="country">
 <result pre="multiple case reports and series from Canada, Europe, Japan, and" exact="the United States" post="have provided early promising results of treatment with remdesivir,"/>
 <result pre="case reports and series from Canada, Europe, Japan, and the" exact="United States" post="have provided early promising results of treatment with remdesivir,"/>
 <result pre="clinical data on LPV/RTV therapy in patients with COVID-19 in" exact="China" post="and Singapore have suggested mixed results.30, 31, 32 Two"/>
 <result pre="on LPV/RTV therapy in patients with COVID-19 in China and" exact="Singapore" post="have suggested mixed results.30, 31, 32 Two retrospective studies"/>
 <result pre="is also being explored. A study of 21 patients in" exact="China" post="receiving tocilizumab in addition to standard of care found"/>
 <result pre="P&amp;lt;.05).59 Conversely, a 21-patient retrospective analysis of tocilizumab treatment in" exact="Italy" post="did not find reductions in ICU admission (P=.22) or"/>
 <result pre="of care.65 However, a retrospective study of 14 patients in" exact="Germany" post="with progressive hyperinflammation due to COVID-19 reported a 58%"/>
 <result pre="SARS-CoV-2.77,78 A publication of a 30-patient RCT of HCQ in" exact="China" post="reported no difference in time to viral clearance, body"/>
 <result pre="retrospective analysis of 95 patients receiving CQ for COVID-19 in" exact="the Netherlands," post="23% of patients had a corrected QT interval exceeding"/>
 <result pre="One arm of a double-blind randomized trial of CQ in" exact="Brazil" post="with a dosage of 600 mg twice daily was"/>
 <result pre="sepsis, this approach may improve mortality rates.102 On March 24," exact="the US" post="Food and Drug Administration made CPT available for use"/>
 <result pre="limited, but increasing. Case series in China, Korea, Mexico, and" exact="the United States" post="have reported varying clinical improvement due to CPT, ranging"/>
 <result pre="but increasing. Case series in China, Korea, Mexico, and the" exact="United States" post="have reported varying clinical improvement due to CPT, ranging"/>
 <result pre="An open-label, multicenter, randomized clinical trial of 101 patients in" exact="China" post="reported clinical improvement on a 6-point scale within 28"/>
 <result pre="a study of 5000 patients receiving CPT as part of" exact="the US" post="Food and Drug Administration Expanded Access Program resulted in"/>
 <result pre="(46) Single 3 (12) Multi 11 (42) Low-dose radiation 12" exact="United States," post="Italy, India, Spain, Iran 3 (25) None 11 (92)"/>
 <result pre="11 (42) Low-dose radiation 12 United States, Italy, India, Spain," exact="Iran" post="3 (25) None 11 (92) Single 0 (0) Multi"/>
 <result pre="therapy (RECOVERY) Trial (International Clinical trials Registry Platform identifier: ISRCTN50189673)" exact="United Kingdom" post="(5000) University of Oxford SoCÂ + LPV/RTVSoCÂ + IFN"/>
 <result pre="Patients at Risk for Severe Disease (HYCOVID) (ClinicalTrials.gov identifier: NCT04325893)" exact="France" post="(1300) University Hospital Angers HCQ Placebo Phase III, multicenter,"/>
 <result pre="Covid-19 Severe SARS-CoV-2 Disease (CONCOVID Study) (ClinicalTrials.gov identifier: NCT04342182) The" exact="Netherlands" post="(426) Erasmus Medical Center COVID-19 convalescent plasma SoC Phase"/>
 <result pre="2Johns Hopkins University &amp;amp; Medicine Coronavirus Resource Center. COVID-19 in" exact="the USA." post="https://coronavirus.jhu.edu. Accessed June 29, 2020 3DengY.LiuW.LiuK.Clinical characteristics of fatal"/>
 <result pre="pneumonia receiving combined Chinese and Western medicine treatmentBiosci Trends1412020646832037389 31YoungB.E.OngS.W.X.KalimuddinS.collab:" exact="Singapore" post="2019 Novel Coronavirus Outbreak Research TeamEpidemiologic features and clinical"/>
 <result pre="Dis7115202076276832161940 48ShiY.TanM.ChenX.Immunopathological characteristics of coronavirus disease 2019 cases in Guangzhou," exact="China" post="[published online ahead of print March 16, 2020]medRxivhttps://doi.org/10.1101/2020.03.12.20034736 49RichardsonP.GriffinI.TuckerC.Baricitinib"/>
 <result pre="open label, randomised controlled trialBMJ3692020m184932409561 81MagagnoliJ.NarendranS.PereiraF.Outcomes of hydroxychloroquine usage in" exact="United States" post="veterans hospitalized with COVID-19 [published online ahead of print"/>
 <result pre="of print May 15, 2020] [published correction appears in Sci" exact="China" post="Life Sci. June 18, 2020. doi:10.1007/s11427-020-1751-3]Sci China Life Scihttps://doi.org/10.1007/s11427-020-1732-2"/>
 <result pre="appears in Sci China Life Sci. June 18, 2020. doi:10.1007/s11427-020-1751-3]Sci" exact="China" post="Life Scihttps://doi.org/10.1007/s11427-020-1732-2 94ChenZ.HuJ.ZhangZ.Efficacy of hydroxychloroquine in patients with COVID-19:"/>
 <result pre="infectionChest15812020e9e1332243945 106YeM.FuD.RenY.Treatment with convalescent plasma for COVID-19 patients in Wuhan," exact="China" post="[published online ahead of print April 15, 2020]J Med"/>
</results>
